Interplay of non-coding RNAs and approved antimetabolites such as gemcitabine and pemetrexed in mesothelioma

Autor: Bernhard Biersack
Jazyk: angličtina
Rok vydání: 2018
Předmět:
0301 basic medicine
Mesothelioma
Bcl-2
B-cell lymphoma 2
DHA
docosahexaenoic acid
Biochemistry
0302 clinical medicine
RA
retinoic acid
TSA
trichostatin A
MPM
malignant pleural mesothelioma
HOTAIR
HOX transcript antisense RNA
SFN
sulforaphane
MALAT1
metastasis-associated lung adenocarcinoma transcript 1
EGCG
epigallocatechin-3-gallate
MicroRNA
Long non-coding RNA
Pemetrexed
DHA - Docosahexaenoic acid
030220 oncology & carcinogenesis
DMPM
diffuse malignant peritoneal mesothelioma
SAHA
suberoylanilide hydroxamic acid
I3C
indole-3-carbinol
PEG
polyethylene glycole
EMT
epithelial-mesenchymal transition
medicine.drug
lcsh:QH426-470
PEITC
phenethylisothiocyanate
NaB
sodium butyrate
DIM
3
3‘-diindolylmethane
Anticancer drugs
AKBA
3-acetyl-11-keto-β-boswellic acid
Article
Tumor resistance
03 medical and health sciences
NSCLC
non-small cell lung cancer
microRNA
Genetics
medicine
PDCD4
programmed cell death 4
Molecular Biology
DADS
diallyl sulfide
business.industry
Biochemistry (medical)
medicine.disease
Gemcitabine
PTEN
phosphatase and tensin homolog
lcsh:Genetics
030104 developmental biology
Non small lung cancer
Cancer research
business
Zdroj: Non-coding RNA Research
Non-coding RNA Research, Vol 3, Iss 4, Pp 213-225 (2018)
ISSN: 2468-0540
Popis: Gemcitabine and pemetrexed are clinically approved antimetabolites for the therapy of mesothelioma diseases. These drugs are often applied in combination with platinum complexes and other drugs. The activity of antimetabolites depended on the expression levels of certain non-coding RNAs, in particular, of small microRNAs (miRNAs) and long non-coding RNAs (lncRNAs). The development of tumor resistance towards antimetabolites was regulated by non-coding RNAs. An overview of the interplay between gemcitabine/pemetrexed antimetabolites and non-coding RNAs in mesothelioma is provided. Further to this, various non-coding RNA-modulating agents are discussed which displayed positive effects on gemcitabine or pemetrexed treatment of mesothelioma diseases. A detailed knowledge of the connections of non-coding RNAs with antimetabolites will be constructive for the design of improved therapies in future. Keywords: MicroRNA, Long non-coding RNA, Mesothelioma, Gemcitabine, Pemetrexed, Anticancer drugs
Databáze: OpenAIRE
Externí odkaz: